Secondary prevention of epidemic gastric cancer in the model of Helicobacter pylori-associated gastritis.

H. pylori Infection, Gastric Cancer and Related Pathologies Dig Dis 2014;32:265–274 DOI: 10.1159/000357857

Secondary Prevention of Epidemic Gastric Cancer in the Model of Helicobacter pylori-Associated Gastritis Marco Pizzi a Deborah Saraggi a Matteo Fassan b Francis Megraud d Francesco Di Mario c Massimo Rugge a a

General Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padova, Padova, ARC-NET Research Centre, University of Verona, Verona, and c Gastroenterology Unit, Department of Medicine, University of Parma, Parma, Italy; d Centre National de Référence des Hélicobacters et Campylobacters, Bordeaux, University of Bordeaux, Bordeaux, France b

Abstract Irrespective of its etiology, long-standing, non-self-limiting gastric inflammation (mostly in Helicobacter pylori-associated cases) is the cancerization ground on which epidemic (intestinal-type) gastric carcinoma (GC) can develop. The natural history of invasive gastric adenocarcinoma encompasses gastritis, atrophic mucosal changes, and intraepithelial neoplasia (IEN). The topography, the extent and the severity of the atrophic changes significantly correlate with the risk of developing both IEN and GC. In recent years, both noninvasive (serological) tests and invasive (endoscopy/biopsy) procedures have been proposed to stratify patients according to different classes of GC risk. As a consequence, different patient-tailored GC secondary prevention strategies have been put forward. This review summarizes the histological features of H. pylori-related gastritis and the natural history of the disease. Histological and serological strategies to assess GC risk as well as the clinical management of atrophic gastritis patients are also discussed. © 2014 S. Karger AG, Basel

© 2014 S. Karger AG, Basel 0257–2753/14/0323–0265$39.50/0 E-Mail [email protected] www.karger.com/ddi

Introduction

Helicobacter pylori-related gastritis is one of the leading precancerous conditions for nonhereditary gastric adenocarcinoma. H. pylori infects approximately 50% of the world’s population, with even higher prevalence in several developing countries [1, 2]. The bacterial colonization consistently results in gastric mucosa inflammation (i.e. gastritis). Due to a complex interplay of both host-related and environmental situations, a subset of the infected patients progresses to more severe organic and functional changes of gastric mucosa, basically consisting in phenotypic modifications of the native population of gastric glands (mucosa atrophy) [3]. Gastric mucosa atrophy is the cancerization ground on which neoplastic gastric transformation (both intraepithelial neoplasia, IEN, and invasive gastric carcinoma, GC) eventually develops [4]. A comprehensive understanding of both the clinical and the biological features of H. pylori-related gastritis is of paramount importance in any consistent assessment of the gastritisassociated GC risk; such a risk stratification is necessarily required in establishing any strategy aimed at secondary prevention of GC [5]. Massimo Rugge Surgical Pathology and Cytopathology Unit Department of Medicine-DIMED, University of Padova Via Aristide Gabelli 61, IT–35121 Padova (PD) (Italy) E-Mail massimo.rugge @ unipd.it

Downloaded by: Ondokuz Mayis Universitesi 193.140.28.22 - 5/9/2014 7:42:43 PM

Key Words Helicobacter pylori · Atrophic gastritis · Gastric cancer · OLGA staging system

b

c

d

Fig. 1. Histological features of native gastric mucosa. a In the gastric antrum, the foveolae occupy one third of the whole mucosal thickness. Both the foveolar and the glandular structures are covered by tall mucus-secreting epithelial cells. b Scattered gastrinproducing G cells are located in the upper portion of the gastric glands. c The oxyntic mucosa is characterized by short foveolar tips and densely packed straight glandular tubules. Glandular structures are mainly composed of principal and parietal cells (insert) that occupy the lower and mid-part of the gland, respectively. Gastric stem cells are located just beneath the foveolar tips. d In the oxyntic mucosa, neuroendocrine enterochromaffin-like cells are located at the glands’ base. HE and immunoperoxidase stain. Original magnification ×20.

This review addresses the phenotypic changes occurring in H. pylori-related gastritis and the natural history of the disease. The stratification of patients according to GC classes of risk and their clinical management will also be addressed.

The Anatomic and Functional Context

Any approach to the description/understanding of gastric inflammatory diseases largely relies on some basic notions concerning the anatomy of gastric mucosa. The surface (luminal) epithelium of gastric mucosa proceeds in the glandular structures, which are embedded in a supporting stromal tissue (lamina propria), surrounding each glandular unit. The muscularis mucosae 266

Dig Dis 2014;32:265–274 DOI: 10.1159/000357857

Pizzi /Saraggi /Fassan /Megraud /Di Mario / Rugge


Color version available online

a

(a thin smooth muscle layer) lies immediately below the lamina propria, forming a continuous rim separating the mucosa from the connective tissue of the submucosa. The luminal surface of the gastric mucosa is covered by columnar epithelia, which also line the tubular folds of the surface epithelium (gastric foveolae). The foveolae continue into the glandular structures. Both surface and glandular epithelial cells rest on a basal membrane, separating the epithelia from the nonepithelial (stromal) mucosa compartment. Glandular structures are embedded within (structurally supported by) a fine meshwork of reticulin and collagen fibers. This supporting tissue (lamina propria) also includes loosely arranged fibroblasts and vascular blood/lymphatic channels. Rare smooth muscle fibers may extend upward from the muscularis mucosae into the lamina propria. A scattered population of leucocytes (histiocytes, lymphocytes, plasma cells, rare polymorphs and mast cells) is dispersed within the stromal interglandular tissue. According to both the phenotype and function of gastric glands, the stomach consists of two distinct anatomical and functional compartments: (a) the distal antropyloric, and (b) the cranial corpus-fundic regions (fig. 1). In both the most proximal and most distal parts of gastric mucosa, however, two additional areas have also been histologically characterized (so-called cardial and juxtapyloric mucosa, respectively). In gastric inflammatory diseases, however, the involvement of these last two regions is basically consistent with that of their adjacent mucosa, which excludes any more detailed description. The transition between antral (mucus-secreting) and corpus (oxyntic) mucosa is not abrupt, and the intervening junctional mucosa is characterized by a mixed glands phenotype [6, 7]. In the antral region, the foveolae occupy approximately one third of the whole mucosal thickness. Both superficial and foveolar columnar epithelia consist of tall mucus-secreting cells, with basally located nuclei. The coiled structures of the antral mucus-secreting glands are embedded within an abundant lamina propria. Glandular coils consist of pale (PAS-positive) epithelia, which produce neutral mucins and bicarbonate [8]. Neuroendocrine gastrin-secreting cells (G cells) are dispersed among the mucin-producing cells. G cells are mainly located in the gland neck, just below the gastric foveolae (fig. 1a, b) [9]. The oxyntic mucosa is characterized by short foveolar tips (less than one quarter of the mucosal thickness) opened into densely packed, straight glandular tubules. Glandular epithelia consist of three distinct cell types, oc-

Gastritis Definition and Etiology

Gastritis is defined as (histologically confirmed) inflammation of the gastric mucosa [17]. Gastric inflammation may result from both transmissible and nontransmissible etiological agents. At the clinical level, gastritis is usually classified as acute and chronic; such a distinction, however, is not supported by any discriminating profile of the inflammatory infiltrate. Consistent with both their etiology and their clinical outcome, gastric inflammatory diseases can be clinically distinguished between self-limiting and non-self-limiting, only the latter being involved in long-term organic and functional alterations of gastric mucosa. Table 1 lists the most common etiological variants of gastric inflammatory diseases.

Histology Profile and Gastritis Natural History

The Inflammatory Trait By definition, the inflammatory infiltrate within the lamina propria (i.e. mononuclear cells and polymorphs) is the necessary pathological trait of gastric inflammatory diseases. The amount of the mononuclear infiltrate (i.e. H. pylori-Related Gastritis

Table 1. Etiological variants of gastric inflammatory conditions

Etiologic category

Agents

Transmissible agents

Virus Bacteria Fungi Parasites

Chemicals

Dietary agents Drugs Bile (biliary reflux)

Physical agents

Radiation

Immune-mediated

Autoimmune Drugs Food-mediated GvHD

Idiopathic

Crohn’s disease Sarcoidosis Vasculitis

GvHD = Graft-versus-host disease.

lymphocytes, plasma cells and histiocytes) defines the gastritis intensity; visual analogue scales have been provided as a useful guide to histologically score the amount of the mononuclear infiltrate (fig. 2a–c). In gastritis of low and moderate intensity, lymphocytes and plasma cells expand the lamina propria, surrounding gastric glands without affecting the overall mucosal architecture; nodular lymphoid aggregates are rarely seen (fig. 2a, b). Structured lymphoid follicles can only be observed in high-intensity gastritis, whose inflammatory infiltrate can even obscure gastric glandular architecture (fig. 2c). Such a situation may affect the ‘quantitative’ histology assessment of gastric units (in such cases a histology categorization of ‘indefinite for atrophy’ has been suggested) [17, 18]. Lymphocytes replacing (or partially destroying) glandular structures (i.e. lymphoepithelial lesions) are highly suggestive of mucosa-associated lymphoid tissue lymphoma (MALT lymphoma, whose pathogenesis is strictly related to H. pylori infection) [19]. Lymphoepithelial lesions should be distinguished from (more bland) intraglandular lymphocytic infiltrate, which is considered the hallmark of lymphocytic gastritis (a peculiar form of gastritis, suggestive of immune-mediated etiology) [20]. Polymorph granulocytes (infiltrating either the lamina propria and/or the glandular lumen) are the well-established markers of the ‘gastritis activity’ [18]. Dig Dis 2014;32:265–274 DOI: 10.1159/000357857

267


cupying different parts of the glands. Just beneath the foveolar tips, the gland isthmus is populated by stem cells which can differentiate into either surface mucus-secreting columnar or deeper ‘specialized’ oxyntic epithelia [10, 11]. The mid-part of the gland (i.e. the neck) includes chloride acid- and intrinsic factor-secreting parietal cells [6, 7]. Parietal cells display striking ultrastructural features: their apical membrane consists of crescent-shaped microvillous canaliculi, and their cytoplasm is occupied by hundreds of mitochondria [12, 13]. The most distal part of the corpus glands (i.e. the base) harbors neuroendocrine cells (i.e. enterochromaffin-like cells) and pepsinogen I (PgI)-producing chief cells (fig. 1c, d) [6, 7]. Gastric glands synthesize and secrete two biochemically and immunologically different types of Pg, the nonactivated precursor of the digestive enzyme pepsin: (a) PgI (also referred to as pepsinogen A), and (b) PgII (or pepsinogen C). While PgI is exclusively secreted by corpus parietal cells, PgII is produced by both the fundic and antral mucosa [14–16]. In the normal stomach, the corpus-fundic compartment is more widespread than the antral one. As a result, the production of PgI (marker of oxyntic mucosa) largely exceeds that of PgII, and the ratio of serum PgI to PgII is about 4:1 [14–16].


Fig. 2. Intensity and activity of gastric inflammatory infiltrates. a–c Lymphocytes,

a

b

c

d

e

f

The gastritis activity can be semiquantitatively scored as mild (granulocytic infiltrate limited to the lamina propria), moderate (granulocytes localized among glandular cells) or severe (intraglandular micro-abscesses; fig. 2d– f). To achieve more consistent interobserver agreement, a two-level scale (low-grade vs. high-grade activity) would be advisable. In H. pylori-associated gastritis, the semiquantitative assessment of H. pylori has been advised. Such a histology score has been demonstrated with no or negligible clinical impact. Successful H. pylori eradication results in the disappearance of the polymorph infiltrate. The persistence of granulocytes is thus indicative of an ongoing H. pylori infection (unsuccessful eradication) [18]. Mucosa Atrophy: Natural History Long-standing inflammation (due to both transmissible and nontransmissible agents) may result in phenotypic (and functional) changes of the epithelial compartment. Irrespective of its etiology, long-standing, non-selflimiting inflammation causes structural damage to the glands’ units (both oxyntic and mucus-secreting), eventually resulting in glandular loss (lamina propria desertification). Alternatively, several inflammation-related molecular deregulations may interfere with the mechanisms modulating the original commitment of the gastric epithelia, resulting in newly appearing phenotypes of the epithelial cells (i.e. gastric epithelial metaplasia). Both of these conditions (gastric mucosa desertification and 268

Dig Dis 2014;32:265–274 DOI: 10.1159/000357857

metaplastic changes of the native gastric glands) result in a loss of the native gland population: the current definition of atrophy as ‘loss of native glands’ includes both of these conditions (fig. 3). In H. pylori-associated gastritis, atrophic changes are featured earlier at the level of the angular (transitional) mucosa (also known as ‘atrophic border’ [21]), later involving the mucus-secreting antral compartment (i.e. antral-restricted atrophic gastritis). The topographical spreading of the atrophic changes is basically consistent with the topography of the earlier inflammatory lesions. As for the antrum to corpus spreading of the inflammatory lesions, also the H. pylori-associated atrophic changes extend proximally from the antrum to the oxyntic mucosa, giving rise to the clinicopathological picture of atrophic multifocal or diffuse atrophic pan-gastritis [22]. Because the corpus-spreading inflammation ‘announces’ H. pylori-dependent oxyntic atrophy, some authors attribute to the nonatrophic corpus gastritis an increased risk of GC (in comparison with the simple antrum-restricted gastritis) [23]. In the model of ‘pure’ (non-H. pylori-associated) autoimmune gastric inflammation, the antrum is virtually unaffected by inflammatory lesions, which basically result from the autoimmune aggression targeted against the parietal cells. As previously described for the H. pylori model, also in this pathological condition, the earlier phase of the (corpus-restricted, immune-mediated) inflammation may progress to atrophic changes (corpusPizzi /Saraggi /Fassan /Megraud /Di Mario / Rugge


plasma cells and monocytes define the intensity of the ongoing inflammatory process. a In low-intensity gastritis, a scanty inflammatory infiltrate is dispersed within the lamina propria. b In moderate-intensity gastritis, the lymphomonocytic infiltrate is more florid without evidence of nodular aggregates that only characterize high-intensity cases (c). d–f Gastritis activity is defined by the presence and the location of polymorph granulocytes. d Mild activity is characterized by granulocytes infiltrating only the lamina propria. e Moderate activity features polymorphs infiltrating the gastric glandular structures. f Severe activity is characterized by intraglandular micro-abscesses (i.e. polymorphs within glandular lumens). HE stain. Original magnification ×20 and ×40.


a

b

Mucosa Atrophy: Histology Phenotypes Gastric mucosa atrophy is defined as ‘loss of native/ appropriate glands’ [17, 18, 24]. This definition is based on the functional and histological heterogeneity of normal gastric mucosa [24–26]. Gastric mucosa atrophy includes two main histological variants: (a) nonmetaplastic, and (b) metaplastic (fig. 3b, c; fig. 4) [24]. Nonmetaplastic atrophy is defined as (partial or complete) disappearance/shrinking of native gastric glands, with fibrotic expansion (i.e. micro-scarring) of the lamina propria. Unlike metaplastic atrophy, the reduced number of ‘appropriate’ glands (antrum: mucus-secreting; corpus: oxyntic) is not accompanied by any change in their original phenotype (fig. 3c; fig. 4a). Nonmetaplastic atrophy should be histologically distinguished from those ‘expansions’ of the lamina propria due to muscularis mucosae hyperplasia, as occurring in chemiH. pylori-Related Gastritis

a

b

c

d

Fig. 4. Histological features of gastric mucosa atrophy. a In nonmetaplastic atrophy, native gastric glands are reduced and substituted by a fibrotic lamina propria. b In IM, the native glandular structures are replaced by well-differentiated intestinal-type epithelia. c Occasionally, both nonmetaplastic and metaplastic (IM) atrophy can be seen. d In pseudo-pyloric metaplasia, the original commitment of oxyntic mucosa can be demonstrated by immunostaining for PgI. HE and immunoperoxidase stain. Original magnification ×10.

Dig Dis 2014;32:265–274 DOI: 10.1159/000357857

269


restricted atrophic gastritis of autoimmune type). Some evidence is available demonstrating that the immunemediated corpus disease could be also related to a longstanding H. pylori infection, able to trigger an autoimmune aggression against structural antigens expressed by parietal cells. This ‘secondary’ immune-mediated corpus gastritis does not exclude ‘primary gastric autoimmunity’, as supported by the consistent demonstration of antiparietal cell autoantibodies, frequently detectable in association with several primary (extragastric) autoimmune diseases.

c


Fig. 3. Histological phenotypes of (atrophic and nonatrophic) gastritis. a Nonatrophic gastritis is characterized by a mixed inflammatory infiltrate within the lamina propria without any loss of appropriate glands. b In metaplastic atrophy, native gastric glands are replaced by fully differentiated glandular structures that are inappropriate for the anatomic location (IM, shown in b, and/or pseudo-pyloric metaplasia). c Nonmetaplastic atrophy is characterized by reduction/shrinkage of native gastric glands that are replaced by a thickened and fibrotic lamina propria. HE. Original magnification ×4.

b

c

d

Fig. 5. Different phenotypes of IM. a On histology, IM is defined

by the presence of mucin-secreting goblet cells (top right), Paneth cells (lower left) or both. b–d According to Felipe and colleagues, IM can be classified based on the different mucin expression profiles. b Type I IM is characterized by goblet cells secreting sialomucins only. c Type II IM features the expression of both sialomucins and sulfomucins. d Type III IM is characterized by goblet and/or columnar cells secreting sulfomucins only. HE, Alcian blue and high-iron diamine stains. Original magnification ×40.

cal/reactive gastropathy, or prolonged proton pump inhibitor administration [17, 27]. The metaplastic variant of gastric atrophy consists in the replacement of native glands by glandular structures featuring a new (anatomically inappropriate) epithelial commitment. While the actual number of glandular units is not necessarily reduced, their phenotype is ‘out of place’ for the anatomic location. A huge amount of epidemiological, clinical and biological studies support the increased neoplastic risk associated with metaplastic transformation: overall, the most basic observation is the strict similarity between intestinalized gastric mucosa and intestinal-type GC. Two main types of inappropriate differentiation (metaplasia) can be found: (a) pseudo-pyloric metaplasia, and/or (b) intestinal metaplasia (IM; fig. 4b–d). By definition, pseudo-pyloric metaplasia (also known as spasmolytic polypeptide-expressing metaplasia) may only affect oxyntic glands (corpus-fundic mucosa). Na270

Dig Dis 2014;32:265–274 DOI: 10.1159/000357857




a

tive oxyntic glands are replaced by antral-like glandular units, lined by mucus-secreting epithelia. The original oxyntic commitment of the metaplastic cells can be demonstrated by their chimerical (scattered) immunohistochemical expression of PgI (fig. 4d) [28, 29]. IM can affect both natively (mucus-secreting) antral and metaplastic (pseudo-antralized) oxyntic epithelia. The histological diagnosis of IM is based on the detection of mucin-producing goblet cells, and/or Paneth cells (fig. 4b, c; fig. 5a) [30]. Based on hematoxylin-eosin (HE) histology, histochemistry and immunohistochemistry, several classifications of gastric IM have been proposed [8, 31–33]. All of them aim at establishing a prognostic link between specific IM variants and elective risk of IM to GC progression. On HE stain, metaplastic columnar and goblet epithelia can be easily distinguished into two phenotypes: the first, more similar to small-bowel mucosa (columnar epithelia featuring brush border, and presence of Paneth cells: small intestinal type, or complete-type IM); the second recalling the cell population of the colonic crypts (absence of brush border, more irregular luminal membrane, absence of Paneth cells: colonic type, or incomplete-type IM) [31]. Matsukura et al. [31] distinguish IM according to the presence/absence of small intestinal enzymes (i.e. sucrose α-D-glucohydrolase, α-trehalase, microsomal aminopeptidase and alkaline phosphatase): (a) the complete-type IM is associated with the full (or nearly full) expression of such enzymes; (b) the incomplete-type IM is characterized by their complete (or almost complete) absence. Sophisticated histochemical techniques subcategorize IM according to its acid mucin secretion, as assessed by high-iron diamine stain (sialomucins: blue stain vs. sulfomucins: brown stain). While such a classification is highly specific in discriminating the mucin secretion, its routine application is significantly limited by two major weaknesses: (a) the chemical reagents involved into the histochemical reaction are potentially toxic, and (b) the mucin pattern assessment is highly subjective due to the frequent occurrence of different mucin patterns in the same single case. According to the acid-mucin expression profiles, Filipe and colleagues distinguish 3 IM variants: (a) type I (with goblet cells secreting sialomucins only); (b) type II (with goblet cells secreting both sialomucins and sulfomucins); (c) type III (with goblet and columnar cells secreting sulfomucins only; fig. 5b–d). Filipe’s type I basically corresponds to complete IM, while types II and III are both included among the Matsukura’s incomplete (colonic-type) IM [8, 33–34].

Atrophic Gastritis and Gastric Carcinogenesis

Intestinal-type (epidemic) GC is triggered by longstanding inflammatory conditions, which, in turn, result in a well-established pattern of phenotypic changes [38]. This sequence of phenotypic and molecular changes is currently known as Correa’s multi-stage cascade of gastric carcinogenesis [3]. In the Correa’s carcinogenic cascade, the initial step is represented by the inflammatory lesions and their associated atrophic progression; the latter is the ‘cancerization ground’ on which advanced precancerous lesions (APLs) and GC finally develop. APLs are considered as phenotypic alterations bridging the gap between atrophic/metaplastic changes and overt invasive carcinoma [3]. Originally defined in the Western literature as epithelial dysplasia [39, 40], APLs are currently referred to as IEN [41]. The diagnosis of gastric IEN is based on the combination of three morphological abnormalities: (a) cytological atypia; (b) loss of the native epithelial commitment, and (c) disruption of mucosal architecture. The severity of these phenotypic changes defines two ‘grades’ of IEN, i.e. low-grade (LG-IEN) and high-grade IEN [42]. The phenotypic and molecular distinction between atypical gastric hyperplasia and LG-IEN can be occasionally challenging. To overcome such diagnostic problems, H. pylori-Related Gastritis

a provisional label of indefinite for IEN has been proposed by two international APL classifications (i.e. the Padova International [42] and Vienna Classification [43]). Two variants of indefinite for IEN lesions have been described: atypical foveolar hyperproliferation (aFH) and hyperproliferative IM (HIM). aFH is usually found in native (i.e. nonmetaplastic) glands undergoing reactive inflammatory modifications; HIM consists of foci of closely packed metaplastic glands, with variable cytological atypia [42]. The long-term follow-up of lesions indefinite for IEN reveals that cases defined as aFH never progress to ‘true-IEN’, whereas a small percentage of hyper-HIM is associated with subsequent progression to LG-IEN (6% of cases) [44].

The Gastritis Staging Systems

Several studies consistently demonstrate that the risk of (intestinal-type) GC significantly correlates with the extent of gastric mucosa atrophy [22, 45, 46]. Building on such observations, an international group of gastroenterologists and pathologists (the Operative Link for Gastritis Assessment, OLGA) has proposed a system for reporting gastric atrophy in terms of stage (the OLGA staging system) [17, 47, 48]. The OLGA stage is obtained by combining the extent of atrophic changes (histological evaluation) with their topographical location (as obtained by a well-established protocol of biopsy sapling of antral and corpus mucosa [49]). A reliable OLGA stage is thus only assessable in the presence of a representative gastric mucosa biopsy sampling. In line with the updated Sydney System biopsy protocol [49], the OLGA Staging System recommends that at least 5 biopsy samples be taken from (a) the greater and lesser curvatures of the distal antrum (2 biopsy cores); (b) the lesser curvature at the incisura angularis (1 biopsy core), and (c) the anterior and posterior walls of the proximal corpus (2 biopsy cores). Additional biopsy samples should be obtained for any focal lesion documented at endoscopy. For each biopsy core, atrophy is assessed as the overall percentage of (metaplastic and nonmetaplastic) atrophic mucosa. The extent of atrophy is scored on a four-tiered scale (score 0: no atrophic glands; score 1: 1–30% of atrophic glands; score 2: 31–60% of atrophic glands; score 3: >60% of atrophic glands). Using this scale, an overall atrophy score is assigned to each gastric anatomic compartment (i.e. the antral and the oxyntic mucosa). The OLGA Dig Dis 2014;32:265–274 DOI: 10.1159/000357857

271


The biological relationship between Filipe’s types of IM is still debated [35–37]. Because different mucin patterns can be faced within the same metaplastic epithelium, it has been suggested that the IM subtypes represent a biological continuum of the same pathophysiological process: in early IM, (native) gastric neutral mucins are replaced by acid sialomucins. As the metaplastic phenotype progresses, sulfomucins become ‘dominant’ and they more closely predict a neoplastic transformation [30]. As such, sulfomucins represent a highly sensitive and specific marker of long-standing metaplastic atrophy, and their presence has been associated with the highest risk of developing GC [8]. Several studies consistently support the assumption that mucin profiling not only correlates with the ‘age’ of the metaplastic transformation, but also significantly correlates with the extent/topography of the gastric intestinalization. This well-established observation significantly lowers the clinical impact of the IM subtyping, also conferring a primary importance to the endoscopy/histology assessment of IM spreading within gastric mucosa.

Score 0: no atrophic glands Score 1: 1–30% of atrophic glands Score 2: 31–60% of atrophic glands

tric mucosa atrophy. The extent of gastric mucosa atrophy is first assessed for each gastric anatomic compartment (i.e. the antropyloric and the corpus-fundic region). The overall OLGA stage is then obtained by matching the antral with the oxyntic atrophy score.

Dig Dis 2014;32:265–274 DOI: 10.1159/000357857

Mild atrophy Moderate atrophy Severe atrophy (score 1) (score 2) (score 3)

No atrophy (score 0) (including incisura angularis)

STAGE 0

STAGE I

STAGE II

STAGE II

Mild atrophy (score 1) (including incisura angularis)

STAGE I

STAGE I

STAGE II

STAGE III

Moderate atrophy (score 2) (including incisura angularis)

STAGE II

STAGE II

STAGE III

STAGE IV

Severe atrophy (score 3) (including incisura angularis)

STAGE III

STAGE III

STAGE IV

STAGE IV

stage is then obtained by matching the antral with the oxyntic atrophy score (fig. 6) [50]. The OLGA system ranks gastritis on a scale of increasing disease severity (from OLGA stage 0 to OLGA stage IV) [50]. Many studies conducted on European, Asian, and South-American populations have demonstrated that patients with high-risk OLGA stages (i.e. OLGA stage III and IV) are at increased risk of both APLs and GC [51–53]. Furthermore, high-risk OLGA stages have also been associated with extensive (cancer-prone) sulfomucin type IM, which further supports their unfavorable prognostic meaning [54]. More recently, by embracing the gastritis staging philosophy, some authors proposed a gastritis staging system based on the sole assessment of IM (the Operative Link on Gastric Intestinal Metaplasia, OLGIM) [55]. Despite its interobserver reproducibility, the OLGIM proposal is significantly less sensitive than the OLGA system in detecting high-risk patients [56]. This reduced sensitivity is mainly attributable to the downstaging of some atrophic nonintestinalized cases (i.e. spasmolytic polypeptide-expressing metaplasia glands) which are actually part of the cancerization process. As recently reported by the Maastricht IV statements, the OLGA staging system provides extremely useful information regarding the extent and severity of atrophic gastritis and contributes to the planning of secondary prevention strategies tailored to each patient’s GC risk: high OLGA stage patients (stage III and IV) should undergo endoscopy-biopsy follow-up, whereas low OLGA stages (stage 0, I and II) can be only clinically or serologically monitored [5].

272

No atrophy (score 0)

Serological Markers for Gastric Mucosa Atrophy

Both the invasiveness and high costs of endoscopy-biopsy procedures limit their widespread use as GC secondary prevention strategies. To overcome such limitations, serological tests have been recently proposed aimed to stratify gastritis patients according to the severity of the gastric mucosa atrophy and, ultimately, according to their atrophy-associated GC risk [5, 57]. These new approaches are largely based on the assessment of the functional status of gastric mucosa as established by serologically testing two main pro-enzymes produced by gastric mucosa: PgI, PgII, and their ratio (PgI/PgII). In particular, serum levels and ratio are linked to the functional status of corpus-fundic glands [58, 59]. Any decrease in oxyntic chief cells (i.e. corpus mucosa atrophy) is indeed paralleled by a reduction of both PgI and the PgI/PgII ratio. Similarly, serum gastrin-17 (G-17) levels correlate with the functional status of gastric antral glands [59, 60]. G-17 (an isoform of the hormone gastrin) is specifically synthesized by antral G cells and its plasma levels are significantly reduced in the presence of severe antrum atrophy. On the contrary, G-17 levels are increased in the case of reduced acid output (i.e. severe corpus-mucosa atrophy), and can be used as a hallmark of autoimmune (corpus-limited) atrophic gastritis [61]. The contemporary assessment of serum PgI/PgII and G-17 levels provides the most comprehensive information regarding the overall status of gastric mucosa, being characterized by a significantly higher sensitivity (71– 83%) than that of the PgI/PgII ratio alone when used to detect (histologically confirmed) gastric mucosa atrophy Pizzi /Saraggi /Fassan /Megraud /Di Mario / Rugge


Fig. 6. The OLGA Staging System for gas-

ANTRUM

Score 3: >60% of atrophic glands

CORPUS


ATROPHY SCORE

[61, 62]. Serum PgI/PgII ratio and G-17 levels can thus be used as first-line screening tests for GC secondary prevention strategies. In the setting of H. pylori-related gastritis, normal PgI/ PgII ratio and G-17 levels virtually exclude gastric mucosa atrophy. Patients featuring this serological picture do not need to undergo invasive endoscopic procedures and should only be clinically followed up. Of note, nonatrophic H. pylori-related gastritis can be associated with increased PgII plasma levels, which can be considered as an accessory indicator of the gastritis activity [63]. A reduced PgI/PgII ratio with low (or fairly normal) G-17 levels can be assumed as a marker of corpus-spreading mucosal atrophy, after an earlier atrophic phase limited to the gastric antrum [52, 58]. As atrophic pan-gastritis is widely recognized as a gastric precancerous condition, all patients with H. pylori infection and low PgI/PgII ratio should be considered at increased risk of GC and should undergo endoscopic-histological examination. Based on the results of the invasive tests, different followup strategies can be planned: (a) patients with histologically documented high-OLGA-stage gastritis should undergo periodical endoscopic follow-up; (b) mild to moderate gastric mucosa atrophy (low OLGA stages) can only be monitored clinically and/or serologically [5, 57].

Conclusions and Future Perspectives

Gastric cancer (GC) is the fourth most common malignancy and the second leading cause of cancer-related death worldwide. More than 90% of GC cases occur sporadically and are associated with long-standing inflammatory conditions (mainly H. pylori infection) [64]. The histological assessment of H. pylori-related gastritis provides clinically and prognostically useful information for a patient-tailored follow-up schedule [5]. In the near future, histology-based secondary prevention strategies will be hopefully flanked by new (less invasive and less expansive) procedures, which will enormously enlarge the population of patients suitable for screening of gastric precancerous conditions (particularly in high-risk countries). The PgI/PgII ratio and G-17 levels (together with anti-H. pylori antibodies) represent promising serological biomarkers, and seminal studies indicate their possible role as first-level tests for the identification of high-risk patients eligible for second-level diagnostic procedures.

Disclosure Statement The authors declare that no financial or other conflict of interest exists in relation to the content of the article.

References

H. pylori-Related Gastritis

8 Jass JR, Filipe MI: The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma. Histochem J 1981;13:9231–9239. 9 Chu S, Schubert ML: Gastric secretion. Curr Opin Gastroenterol 2012;28:587–593. 10 Qiao XT, Gumucio DL: Current molecular markers for gastric progenitor cells and gastric cancer stem cells. J Gastroenterol 2011;46: 855–865. 11 Han ME, Oh SO: Gastric stem cells and gastric cancer stem cells. Anat Cell Biol 2013;46:8–18. 12 Miller ML, Andringa A, Zavros Y, et al: Volume density, distribution, and ultrastructure of secretory and basolateral membranes and mitochondria predict parietal cell secretory (dys)function. J Biomed Biotechnol 2010; 2010:394198. 13 Madsen KM, Tisher CC: Structure-function relationships in H+-secreting epithelia. Fed Proc 1985;44:2704–2709. 14 Gritti I, Banfi G, Roi GS: Pepsinogens: physiology, pharmacology pathophysiology and exercise. Pharmacol Res 2000;41:265–281. 15 Samloff IM: Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology 1971; 61:185–188.

Dig Dis 2014;32:265–274 DOI: 10.1159/000357857

16 Samloff IM, Liebman WM: Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology 1973;65:36–42. 17 Rugge M, Genta RM: Staging and grading of chronic gastritis. Hum Pathol 2005; 36: 228– 233. 18 Rugge M, Pennelli G, Pilozzi E, et al: Gastritis: the histology report. Dig Liver Dis 2011; 43(suppl 4):S373–S384. 19 Ferreri AJ, Govi S, Ponzoni M: Marginal zone lymphomas and infectious agents. Semin Cancer Biol 2013;23:431–440. 20 Wu TT, Hamilton SR: Lymphocytic gastritis: association with etiology and topology. Am J Surg Pathol 1999;23:153–158. 21 Kimura K, Satoh K, Ido K, et al: Gastritis in the Japanese stomach. Scand J Gastroenterol Suppl 1996;214:17–20. 22 Correa P, Piazuelo MB: Natural history of Helicobacter pylori infection. Dig Liver Dis 2008; 40:490–496. 23 Uemura N, Okamoto S, Yamamoto S: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784– 789.

273


1 Calvet X, Ramírez Lázaro MJ, Lehours P, et al: Diagnosis and epidemiology of Helicobacter pylori infection. Helicobacter 2013; 18(suppl 1):5–11. 2 Brown LM: Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 2000;22:283–297. 3 Correa P: The biological model of gastric carcinogenesis. IARC Sci Publ 2004; 157: 301– 310. 4 Rugge M, Capelle LG, Cappellesso R, et al: Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol 2013; 27: 205– 223. 5 Rugge M, Fassan M, Graham DY: Clinical guidelines: secondary prevention of gastric cancer. Nat Rev Gastroenterol Hepatol 2012; 9:128–129. 6 Owen DA: Stomach; in Mills SE (ed): Histology for Pathologists, ed 3. Philadelphia, Lippincott Williams & Wilkins, 2007, pp 589– 602. 7 Khurana S, Mills JC: The gastric mucosa development and differentiation. Prog Mol Biol Transl Sci 2010;96:93–115.

274

Dig Dis 2014;32:265–274 DOI: 10.1159/000357857

38 Vannella L, Lahner E, Osborn J, et al: Risk factors for progression to gastric neoplastic lesions in patients with atrophic gastritis. Aliment Pharmacol Ther 2010;31:1042–1050. 39 Morson BC, Sobin LH, Grundmann E, et al: Precancerous conditions and epithelial dysplasia in the stomach. J Clin Pathol 1980; 33: 711–721. 40 Lauwers GY, Riddell RH: Gastric epithelial dysplasia. Gut 1999;45:784–790. 41 Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO Classification of Tumours of the Digestive System. Lyon, International Agency for Research on Cancer, 2010. 42 Rugge M, Correa P, Dixon MF, et al: Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000;24:167–176. 43 Schlemper RJ, Riddell RH, Kato Y, et al: The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47:251–255. 44 Fassan M, Pizzi M, Farinati F, et al: Lesions indefinite for intraepithelial neoplasia and OLGA staging for gastric atrophy. Am J Clin Pathol 2012;137:727–732. 45 Miehlke S, Hackelsberger A, Meining A, et al: Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. Br J Cancer 1998;78: 263–266. 46 Cassaro M, Rugge M, Gutierrez O, et al: Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000; 95:1431–1438. 47 Genta RM, Rugge M: Assessing risks for gastric cancer: new tools for pathologists. World J Gastroenterol 2006;12:5622–5627. 48 Rugge M, Genta RM, OLGA-Group: Staging gastritis: an international proposal. Gastroenterology 2005;129:1807–1808. 49 Dixon MF, Genta RM, Yardley JH, et al: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161–1181. 50 Rugge M, Correa P, Di Mario F, et al: OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008;40:650–658. 51 Kodama M, Murakami K, Okimoto T, et al: Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer. Scand J Gastroenterol 2013;48:1249–1256. 52 Rugge M, de Boni M, Pennelli G, et al: Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010; 31: 1104–1111.

53 Rugge M, Kim JG, Mahachai V, et al: OLGA gastritis staging in young adults and countryspecific gastric cancer risk. Int J Surg Pathol 2008;16:150–154. 54 Rugge M, Fassan M, Pizzi M, et al: Operative Link for Gastritis Assessment gastritis staging incorporates intestinal metaplasia subtyping. Hum Pathol 2011;42:1539–1544. 55 Capelle LG, de Vries AC, Haringsma J, et al: The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010;71:1150–1158. 56 Rugge M, Fassan M, Pizzi M, et al: Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol 2011;17:4596–4601. 57 Agréus L, Kuipers EJ, Kupcinskas L, et al: Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol 2012;47:136– 147. 58 Miki K, Fujishiro M, Kodashima S, et al: Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc 2009;21:78–81. 59 Sipponen P, Ranta P, Helske T, et al: Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational casecontrol study. Scand J Gastroenterol 2002;37: 785–791. 60 Kikuchi R, Abe Y, Iijima K, et al: Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with highrisk of early gastric cancer. Tohoku J Exp Med 2011;223:35–44. 61 Väänänen H, Vauhkonen M, Helske T, et al: Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003;15:885–891. 62 Storskrubb T, Aro P, Ronkainen J, Sipponen P, et al: Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: the Kalixanda study. Scand J Gastroenterol 2008;43:1448–1455. 63 Di Mario F, Cavallaro LG, Moussa AM, et al: Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium. Dig Dis Sci 2006; 51: 1791– 1795. 64 de Martel C, Forman D, Plummer M: Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am 2013;42:219–240.



24 Rugge M, Correa P, Dixon MF, et al: Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002; 16: 1249– 1259. 25 Ruiz B, Garay J, Correa P, et al: Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. Am J Gastroenterol 2001;96:3281–3287. 26 Rugge M, Meggio A, Pennelli G, et al: Gastritis staging in clinical practice: the OLGA staging system. Gut 2007;56:631–636. 27 Genta RM: Differential diagnosis of reactive gastropathy. Semin Diagn Pathol 2005; 22: 273–283. 28 Weis VG, Goldenring JR: Current understanding of SPEM and its standing in the preneoplastic process. Gastric Cancer 2009; 12: 189–197. 29 Nam KT, Lee HJ, Sousa JF, et al: Mature chief cells are cryptic progenitors for metaplasia in the stomach. Gastroenterology 2010; 139: 2028–2037. 30 Correa P, Piazuelo MB, Wilson KT: Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol 2010;105:493– 498. 31 Matsukura N, Suzuki K, Kawachi T, et al: Distribution of marker enzymes and mucin in intestinal metaplasia in human stomach and relation to complete and incomplete types of intestinal metaplasia to minute gastric carcinomas. J Natl Cancer Inst 1980;65:231–240. 32 Filipe MI, Munoz N, Matko I, et al: Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994; 57:324–329. 33 Jass JR, Filipe MI: Sulphomucins and precancerous lesions of the human stomach. Histopathology 1980;4:271–279. 34 LeungWK, Sung JJY: Intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther 2002;16:1209–1216. 35 Gutierrez-Gonzalez L, Wright NA: Biology of intestinal metaplasia in 2008: more than a simple phenotypic alteration. Dig Liver Dis 2008;40:510–522. 36 Silva E, Teixeira A, David L, et al: Mucins as key molecules for the classification of intestinal metaplasia of the stomach. Virchows Arch 2002;440:311–317. 37 Piazuelo MB, Haque S, Delgado A, et al: Phenotypic differences between esophageal and gastric intestinal metaplasia. Mod Pathol 2004;17:62–74.

Helicobacter pylori infection and chronic gastritis in gastric cancer.

Helicobacter gastritis and intestinal metaplasia in a gastric cancer family.

Helicobacter pylori gastritis and gastric MALT-lymphoma.

Helicobacter pylori eradication: gastric cancer prevention.

Helicobacter felis gastritis in gnotobiotic rats: an animal model of Helicobacter pylori gastritis.

Helicobacter mustelae-associated gastritis in ferrets. An animal model of Helicobacter pylori gastritis in humans.

[Emphysematous gastritis secondary to gastric mucormycosis].

Gene polymorphisms of micrornas in Helicobacter pylori-induced high risk atrophic gastritis and gastric cancer.

Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development.

Helicobacter pylori gastritis mimicking gastric carcinoma at CT evaluation.

Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma.

Efficacy of Helicobacter pylori eradication for the prevention of metachronous gastric cancer after endoscopic resection for early gastric cancer.

Gastric emptying in patients with fundal gastritis and gastric cancer.

[Helicobacter pylori infection and endoscopic gastritis -Kyoto classification of gastritis].

Gastritis in the alcoholic: relationship to gastric alcohol metabolism and Helicobacter pylori.

Helicobacter mustelae-induced gastritis and elevated gastric pH in the ferret (Mustela putorius furo).

Phlegmonous Gastritis with Early Gastric Cancer.

Genetic and molecular aspects of Helicobacter pylori in gastritis, pre- cancerous conditions and gastric adenocrcinoma.

Helicobacter pylori Associated Gastritis in Northern Maharashtra, India: A Histopathological Study of Gastric Mucosal Biopsies.

Prevention of gastric cancer.

Nodular gastritis and Helicobacter pylori.

Helicobacter pylori and Gastric Cancer.

Helicobacter pylori Eradication for Prevention of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer.

Protein signature characterizing Helicobacter pylori strains of patients with autoimmune atrophic gastritis, duodenal ulcer and gastric cancer.